April 5 (Reuters) - Johnson & Johnson:

* JOHNSON & JOHNSON TO ACQUIRE SHOCKWAVE MEDICAL

* J&J: PROPOSED DEAL FOR $335.00 PER SHARE IN CASH,

* J&J - PROPOSED DEAL FOR $13.1 BILLION

* J&J - PROPOSED DEAL FOR ENTERPRISE VALUE OF APPROXIMATELY

$13.1

BILLION INCLUDING CASH ACQUIRED

* J&J: PROPOSED DEAL FOR ENTERPRISE VALUE OF APPROXIMATELY

$13.1

BILLION INCLUDING CASH ACQUIRED

* J&J - TRANSACTION WILL BE ACCRETIVE TO OPERATING MARGIN

FOR BOTH

JOHNSON & JOHNSON AND JOHNSON ( JNJ ) & JOHNSON MEDTECH

* J&J: EXPECTS TO FUND TRANSACTION THROUGH A COMBINATION OF

CASH

ON HAND AND DEBT

* J&J - CLOSING OF TRANSACTION IS EXPECTED TO OCCUR BY

MID-YEAR

2024

* J&J: DEAL EXPECTED TO DILUTE ADJUSTED EARNINGS PER SHARE

BY

ABOUT $0.10 IN 2024 AND APPROXIMATELY $0.17 IN 2025

* J&J: SHOCKWAVE WILL OPERATE AS A BUSINESS UNIT WITHIN

JOHNSON &

JOHNSON MEDTECH

* J&J: MICHAEL BODNER WILL ASSUME RESPONSIBILITY FOR

SHOCKWAVE

UPON CLOSE

* J&J - ISAAC ZACHARIAS WILL TRANSITION TO BECOME WORLDWIDE

PRESIDENT OF SHOCKWAVE, REPORTING TO MICHAEL BODNER

* J&J: DOUG GODSHALL, SHOCKWAVE'S PRESIDENT AND CHIEF

EXECUTIVE

OFFICER, WILL ADVISE THROUGH TRANSITION

* J&J - FOLLOWING COMPLETION OF TRANSACTION, SHOCKWAVE'S

COMMON

STOCK WILL NO LONGER BE LISTED FOR TRADING ON NASDAQ GLOBAL

SELECT MARKET

Source text for Eikon:

Further company coverage: